Patents by Inventor Stephen Paul Cobbold

Stephen Paul Cobbold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric antibody, pharmaceutical composition and process of its production
    Patent number: 7098006
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 29, 2006
    Assignee: Burroughs Wellcome Co.
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: 6767996
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: May 17, 1993
    Date of Patent: July 27, 2004
    Assignee: Glaxo Wellcome Inc.
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Non-depleting anti-CD4 monoclonal antibodies and tolerance induction
    Patent number: 6056956
    Abstract: Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depleting CD8 monoclonal antibody may be administered prior to the non-depleting antibodies.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 2, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Stephen Paul Cobbold, Herman Waldmann
  • Monoclonal antibodies for inducing tolerance
    Patent number: 5690933
    Abstract: Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depicting CD8 monoclonal antibody may be administered prior to the non-depleting antibodies.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: November 25, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Stephen Paul Cobbold, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: RE43898
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: January 1, 2013
    Assignee: Glaxo Wellcome Inc. Research
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
  • Altered antibodies and their preparation
    Patent number: RE46877
    Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 29, 2018
    Assignee: BTG INTERNATIONAL LIMITED
    Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann